All News

At the 2025 SPPCP Virtual Conference, Carolyn Hall, PharmD, BCPS, and Maria Felton Lowry, PharmD, BCPS, BCGP, presented a comprehensive and practical framework for pharmacy professionals to build effective, adaptable mentorship relationships.

Yuflyma gains FDA interchangeability with Humira, enhancing patient access to effective biosimilar treatments for various inflammatory conditions.

With each increase in lipoprotein(a) level in patients with atherosclerotic cardiovascular disease (ASCVD), there was a corresponding increase in risk of experiencing an ASCVD event.

Trastuzumab deruxtecan (T-DXd) yielded favorable outcomes and improved survival rates.

Cefepime-taniborbactam shows promise against resistant infections, but more studies are needed.

The phase 3 REAL8 trial shows once-weekly Sogroya effectively improves growth in children with growth disorders, offering a promising alternative to daily injections.

Additional intravenous immunoglobulin (IVIG) treatment shows promise for patients with Kawasaki disease who are resistant to infliximab, potentially matching the efficacy of second IVIG doses in patients resistant to IVIG.

The report highlights the expanding role of pharmacists in navigating regulatory, financial, logistical, and clinical complexities to ensure safe, equitable, and effective delivery of cell and gene therapies amid a rapidly growing and evolving treatment landscape.

Counseling for behavior change helps patients understand the importance of their medications and make positive changes.

In a session at the 2025 Virtual Conference on Pain and Palliative Care, Isabella Zerfas, PharmD, and Abbey Galligan, PharmD, BCPS, explore effective pain management strategies for opioid use disorder (OUD) and complex persistent opioid dependence.

Experts emphasize the importance of tailored vaccination strategies for pneumococcal based on individual risk factors.

RSV vaccination for older adults requires understanding risk factors, using empathetic communication strategies, and proactively identifying eligible patients through careful review of medical histories and care transitions.

Vo discusses how research and mentorship can enhance practice and patient care.

In a major policy shift, officials from the FDA announced a new regulatory framework for COVID-19 vaccinations, prioritizing adults 65 years and older and individuals with serious comorbidities putting them at high risk for severe COVID-19.

The data were presented at the ESMO Breast Cancer 2025 Annual Meeting.

In premenopausal women, denosumab significantly prevented bone loss and microarchitectural deterioration.

Studies suggest that prolonged activation of MUC1-C encourages disease progression.

The risk of cardiovascular disease (CVD) was higher among those who were exposed to assisted reproductive technology.

The treatment could hold significant potential for major depressive disorder

The combination demonstrated improved efficacy compared with ruxolitinib as a monotherapy.

Research reveals pioglitazone, a diabetes drug, may slow prostate cancer progression, offering new hope for patients with both conditions.

Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.

A new triple-combination therapy shows promise in improving asthma management, offering hope for millions with uncontrolled symptoms.

Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, received a leadership award at the 2025 HOPA Annual Meeting.

A systematic review reveals declining pediatric pneumococcal complicated pneumonia rates following the introduction of pneumococcal conjugate vaccine 13.

Diabetic ketoacidosis poses serious risks for patients with diabetes, requiring urgent treatment to prevent life-threatening complications and ensure recovery.

Health care professionals play a vital role in preventing overdose and ensuring safe use.